シングレアなどのLT拮抗剤が自殺リスク増加の可能性?・・・結構、つかってるので、影響が大きい。シングレアと自殺 2008年 03月 31日でも触れたので、最初ではないのだが・・・

Early Communication About an Ongoing Safety Review of Montelukast (Singulair)


 Merk社は添付文書患者向け情報などに市販後副事象である、振戦 (March 2007)、うつ(April 2007)、自殺傾向 (自殺念慮、自殺行動) (October 2007)、不安(February 2008).の記載をしている。

This information reflects FDA’s current analysis of available data concerning these drugs. Posting this information does not mean that FDA has concluded there is a causal relationship between the drug product and the emerging safety issue. Nor does it mean that FDA is advising health care professionals to discontinue prescribing this product. FDA is considering, but has not reached a conclusion about whether this information warrants any regulatory action. FDA intends to update this document when additional information or analyses become available.



by internalmedicine | 2009-01-19 16:03 | 呼吸器系  

<< 馬鹿マスコミ:リレンザを安易に... 肥満に関する、新たな7つの座位... >>